Abstract
Since the first human catheterization performed by Forssman in 1929 angioplasty equipment and medical therapies have undergone considerable evolution and technical improvement allowing interventionalists to perform more complex procedures and solving most of the percutaneous limitations. While percutaneous coronary intervention (PCI) has dramatically changed the outcome in the Acute Coronary Syndrome (ACS) setting, its role in the treatment of chronic stable angina is still debated. Stable coronary artery disease (SCAD) is a major public health issue and its prevalence is still increasing in the industrialized world. The correct treatment sees a multi-strategy approach aimed to a relief of symptoms, prevention of future cardiac events and survival improvement. In so forth, treatment strategies include optimal medical therapy (OMT) alone or combined with percutaneous or surgical coronary revascularization. Despite this, angina remains poorly controlled in the vast majority of CAD patients. Traditional agents such Beta-blockers or Calcium channel blockers or short and long acting nitrates have been used as first-line anti-anginal therapy for several years. Nowadays newer and more effective drugs usually used on top of older medical treatment have become available.
Keywords: Acute coronary syndrome, coronary revascularization, new anti-anginal drugs, percutaneous coronary intervention, stable angina, unstable angina.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization
Volume: 13 Issue: 1
Author(s): Gioel Gabrio Secco, Rosario Parisi, Francesca Mirabella, Andrea Rognoni, Alessandro Lupi, Giuseppe De Luca, Paolo Nicola Marino, Rossella Fattori, Alberto Cremonesi and Fausto Castriota
Affiliation:
Keywords: Acute coronary syndrome, coronary revascularization, new anti-anginal drugs, percutaneous coronary intervention, stable angina, unstable angina.
Abstract: Since the first human catheterization performed by Forssman in 1929 angioplasty equipment and medical therapies have undergone considerable evolution and technical improvement allowing interventionalists to perform more complex procedures and solving most of the percutaneous limitations. While percutaneous coronary intervention (PCI) has dramatically changed the outcome in the Acute Coronary Syndrome (ACS) setting, its role in the treatment of chronic stable angina is still debated. Stable coronary artery disease (SCAD) is a major public health issue and its prevalence is still increasing in the industrialized world. The correct treatment sees a multi-strategy approach aimed to a relief of symptoms, prevention of future cardiac events and survival improvement. In so forth, treatment strategies include optimal medical therapy (OMT) alone or combined with percutaneous or surgical coronary revascularization. Despite this, angina remains poorly controlled in the vast majority of CAD patients. Traditional agents such Beta-blockers or Calcium channel blockers or short and long acting nitrates have been used as first-line anti-anginal therapy for several years. Nowadays newer and more effective drugs usually used on top of older medical treatment have become available.
Export Options
About this article
Cite this article as:
Secco Gabrio Gioel, Parisi Rosario, Mirabella Francesca, Rognoni Andrea, Lupi Alessandro, De Luca Giuseppe, Marino Nicola Paolo, Fattori Rossella, Cremonesi Alberto and Castriota Fausto, Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (1) . https://dx.doi.org/10.2174/1871525713666141219114240
DOI https://dx.doi.org/10.2174/1871525713666141219114240 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Parvalbumin as a Pleomorphic Protein
Current Protein & Peptide Science Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design NMR of Membrane-Associated Peptides and Proteins
Current Protein & Peptide Science Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A
Current Vascular Pharmacology Inhibitors of Mammalian Acetyl-CoA Carboxylase
Recent Patents on Cardiovascular Drug Discovery Puerarin Stimulates Osteogenic Differentiation and Bone Formation Through the ERK1/2 and p38-MAPK Signaling Pathways
Current Molecular Medicine Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Biological Activities of Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Opportunities and Challenges for Niosomes as Drug Delivery Systems
Current Drug Delivery Humans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical Design Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Coal Mine Dust Lung Disease: The Silent Coal Mining Disaster
Current Respiratory Medicine Reviews Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews